Unichem Laboratories Reports Q2 FY27 Results: Consolidated PAT Reaches ₹22.22 Crore
Unichem Laboratories Ltd · Financial Result · 04 Nov 2026, 7:31 pm
Unichem Laboratories Reports Q2 FY27 Results: Consolidated PAT Reaches ₹22.22 Crore Unichem Laboratories reported consolidated revenue from operations of ₹640.22 crore for Q2 ended 30th Sep'26, up 10.58% YoY from ₹578.96 crore and up 1.20% QoQ. Consolidated profit before exceptional items stood at ₹51.63 crore versus ₹47.44 crore in Q2 FY26. Following an exceptional claim provision of ₹24.26 crore related to UK Perindopril litigation by subsidiary Niche Generics, net profit after tax reached ₹22.22 crore, rebounding from a loss of ₹11.89 crore YoY. Standalone revenue grew 12.61% YoY to ₹401.90 crore with PAT of ₹1.49 crore.
Original exchange filing (PDF)
More announcements from Unichem Laboratories Ltd
- Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026. · 04 Nov 2026
- Unichem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- To consider and approve the unaudited financial results for the period ended September 30, 2026 · 04 Nov 2026
- UNICHEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 04 Nov 2026
- Unichem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Board Meeting Intimation .... · 04 Nov 2026
- Announcement under regulation 30 (LODR) - USFDA Inspection at Goa formulation Facility · 26 Sept 2026
- Disclosure u/r. 30 of SEBI (LODR) Regulations, 2015 · 19 Sept 2026
- Extension of the Exercise period for the options granted and vested under Unichem Employee Stock Option Scheme 2018. · 11 Sept 2026
